Comparison of 1-week vs. 2-or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication

被引:9
|
作者
Kamberoglou, D
Polymeros, D
Sanidas, I
Doulgeroglou, V
Savva, S
Patra, E
Tzias, V
机构
[1] 1st IKA Hosp, Dept Gastrointestinal Endoscopy, Athens, Greece
[2] Amalia Fleming Hosp, Dept Pathol, Athens, Greece
关键词
D O I
10.1046/j.1365-2036.2001.01072.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Helicobacter pylori eradication therapies based on ranitidine bismuth citrate have recently been introduced in clinical practice. Aim: To compare the efficacy of three regimens containing ranitidine bismuth citrate given for 1, 2 and 4 weeks, combined with two antibiotics for the first week, in the eradication of H. pylori. Methods: Eighty-six consecutive patients (50 duodenal ulcer disease, 36 non-ulcer dyspepsia) with H. pylori infection were offered three eradication regimens: (a) 1-week group (n = 2 8), ranitidine bismuth citrate 400 mg b.d. for 7 days; (b) 2-week group (n = 29), ranitidine bismuth citrate 400 mg: b.d. for 14 days; and (c) 4-week group (n = 29), ranitidine bismuth citrate 400 mg b.d. for 28 days. In all patients, clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. were given for the first week. Endoscopy was repeated 1 month after the end of treatment and eradication was considered to be successful if both rapid urease test and histology were negative. Results: Overall, H. pylori was eradicated in 84% (72/86) patients on intention-to-treat analysis, whereas the per protocol cure rate was 89% (72/81). Eradication rates were 23/27 (85%) (95% confidence interval (Cl): 66-96%), 25/27 (92%) (95% Cl: 76-99%) and 24/27 (89%) (95% CI: 71-98%) in the 1-, 2- and 4-week groups, respectively, on per protocol analysis, and 25/28 (82%) (95% CI: 63-94%), 25/29 (86%) (95% CI: 68-96%) and 24/29 (83%) (95% CI: 64-94%), respectively, on intention-to-treat analysis (P > 0.05, N.S.). No significant differences were observed between groups concerning duodenal ulcer healing, resolution of symptoms and adverse effects. Conclusions: The 1-week regimen with ranitidine bismuth citrate, clarithromycin and metronidazole is effective in H. pylori eradication. Prolongation of treatment with ranitidine bismuth citrate for 2 or 4 weeks does not achieve a statistically significant more favourable outcome.
引用
收藏
页码:1493 / 1497
页数:5
相关论文
共 50 条
  • [31] Effect of 1-week triple therapy for Helicobacter pylori infection with lansoprazole or ranitidine and clarithromycin and metronidazole
    Kihira, K
    Kimura, K
    Satoh, K
    Takimoto, T
    Saifuku, K
    Taniguchi, Y
    Kojima, T
    Tokumaru, K
    Yamamoto, H
    GASTROENTEROLOGY, 1996, 110 (04) : A154 - A154
  • [32] Retreatment after failure of Helicobacter pylori eradication: Quadruple vs ranitidine bismuth citrate 2 weeks therapy.
    Di Mario, F
    Salandin, S
    Dal Bo', N
    Battaglia, G
    Pilotto, A
    Franceschi, M
    Andrea, S
    Grassi, SASA
    De Bastiani, R
    Leandro, G
    Rugge, M
    GASTROENTEROLOGY, 1999, 116 (04) : A149 - A149
  • [33] 2-week is better than 1-week triple therapy for H. pylori eradication
    Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4 (4): : 180 - 180
  • [34] Two-week Triple Therapy has a Higher Helicobacter pylori Eradication Rate Than 1-week Therapy: A Single-center Randomized Study
    Wang, Jiaofeng
    Zhang, Gansheng
    Hu, Xiaona
    Liu, Ye
    Bao, Zhijun
    Huang, Yiqin
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2015, 21 (06): : 355 - 359
  • [35] Systematic review and meta-analysis:: Proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication
    Gisbert, JP
    Gonzalez, L
    Calvet, X
    Pajares, JM
    HELICOBACTER, 2005, 10 (05) : 529 - 530
  • [36] Systematic review and meta-analysis:: Proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication
    Gisbert, JP
    Moreno, L
    Calvet, X
    GASTROENTEROLOGY, 2005, 128 (04) : A427 - A427
  • [37] Optimal compliance eliminates differences in eradication rates between 2-week dual and 1-week triple therapy for Helicobacter pylori gastritis
    Erdag, S
    Bojko, JB
    Burlage, M
    Schwarzhoff, R
    Braden, B
    Lembeke, B
    Folsch, UR
    Schmidt, WE
    GASTROENTEROLOGY, 1996, 110 (04) : A103 - A103
  • [38] One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance
    Wong, BCY
    Wong, WM
    Wang, WH
    Fung, FMY
    Lai, KC
    Chu, KM
    Yuen, ST
    Leung, SY
    Hu, WHC
    Yuen, MF
    Lau, GKK
    Chan, CK
    Lam, SK
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (03) : 403 - 409
  • [39] 1-week vs. 2-week bismuth subsalicylate-based triple therapy for H-pylori:: Results of a US randomized trial.
    Yang, R
    Hamamoto, R
    Laine, L
    GASTROENTEROLOGY, 1998, 114 (04) : A340 - A340
  • [40] One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese
    Hung, WK
    Wong, WM
    Wong, GSW
    Yip, AWC
    Szeto, ML
    Lai, KC
    Hu, WHC
    Chan, CK
    Xia, HHX
    Yuen, MF
    Fung, FMY
    Tong, TSM
    Ho, VYK
    Lam, SK
    Wong, BCY
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (12) : 2067 - 2072